Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India.

Background: () strains resistant to isoniazid and rifampin (multidrug-resistant tuberculosis [MDR-TB]) are increasingly reported worldwide, requiring renewed focus on the nuances of drug resistance. Patients with low-level moxifloxacin resistance may benefit from higher doses, but limited clinical data on this strategy are available.

Methods: We conducted a 5-year observational cohort study of MDR-TB patients at a tertiary care center in India.

Cycloserine did not increase depression incidence or severity at standard dosing for multidrug-resistant tuberculosis.

https://bit.ly/3GtQmOH